Inhibition of bacterial adherence on the surface of stents and bacterial growth in bile by bismuth dimercaprol.
Bacterial infection and biofilm formation on the surface of biliary stents is believed to be one of the main factors in stent occlusion. This study explored the role of the new reagent, bismuth dimercaprol, in preventing bacterial adherence and bacterial biofilm formation on the surface of biliary stents. Sterile porcine bile preparations, infected separately with Escherichia coli, Klebsiella pneumoniae, Enterobacter, and Enterococcus, were used as the perfusion media in an in vitro perfusion system. The bacterial growth in the media and the bacterial adherence on the surface of stents were tested when different concentrations of bismuth dimercaprol were used in the perfusion media. BisBAL (5 microM) did not inhibit the growth of any of the tested bacterial species. It did, however, significantly decrease the amount of bacteria adhering to the surface of stents for all bacterial strains except Escherichia coli. Bismuth dimercaprol (20 microM) significantly inhibited the growth of Escherichia coli, Klebsiella pneumoniae, and Enterobacter and, thereby, significantly decreased the amount of these bacteria adhering to the surface of stents. The unique bactericidal and anitbiofilm activities of bismuth thiols might contribute to delaying the process of biliary stent occlusion if the effective concentrations of bismuth thiols could be delivered to the target sites. The feasibility of this application of bismuth thiols deserves further investigation.
ENH Research Institute, Northwestern University Feinberg School of Medicine, Evanston, Illinois 60201, USA.
Hongjun
H
Zhang
Javon
J
Tang
Xangwen
X
Meng
Jackie
J
Tsang
Tat-Kin
TK
Tsang
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001422:Bacterial Adhesion / Q000187:drug effects*; D001424:Bacterial Infections; D001646:Bile / Q000187:drug effects / Q000382:microbiology*; D018441:Biofilms / Q000187:drug effects* / Q000254:growth & development; D001729:Bismuth; D004112:Dimercaprol / Q000031:analogs & derivatives* / Q000494:pharmacology*; D004338:Drug Combinations; D004755:Enterobacteriaceae / Q000187:drug effects / Q000502:physiology; D016983:Enterococcus / Q000187:drug effects / Q000502:physiology; D004866:Equipment Contamination; D066298:In Vitro Techniques; D009942:Organometallic Compounds / Q000494:pharmacology*; D011475:Prosthesis Failure; D016459:Prosthesis-Related Infections / Q000209:etiology; D015607:Stents / Q000009:adverse effects*; D013552:Swine
D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D009942:Organometallic Compounds; C103324:bismuth dimercaptopropanol; D004112:Dimercaprol; D001729:Bismuth